References
Aiyar J, Nguyen AN, Chandy KG, & Grissmer S (1994). The P-region and S6
of Kv3.1 contribute to the formation of the ion conduction pathway.Biophys J, 67(6), 2261-2264.
Arias C, Guizy M, David M, Marzian S, Gonzalez T, Decher N, &
Valenzuela C (2007). Kvbeta1.3 reduces the degree of stereoselective
bupivacaine block of Kv1.5 channels. Anesthesiology, 107(4),
641-651.
Baukrowitz T, & Yellen G (1996). Two functionally distinct subsites for
the binding of internal blockers to the pore of voltage-activated
K+ channels. Proc Natl Acad Sci USA, 93(23),
13357-13361.
Bowers KJ, Chow DE, Xu H, Dror RO, Eastwood M, Gregersen BA, …
Sacerdoti FD (2006). Scalable Algorithms for Molecular Dynamics
Simulations on Commodity Clusters. ACM/IEEE SC 2006 Conference
(SC’06), IEEE, 2006(43.
Caballero R, Moreno I, Gonzalez T, Valenzuela C, Tamargo J, & Delpon E
(2002). Putative binding sites for benzocaine on a human cardiac cloned
channel (Kv1.5). Cardiovasc Res, 56(1), 104-117.
Caballero R, Valenzuela C, Longobardo M, Tamargo J, & Delpon E (1999).
Effects of rupatadine, a new dual antagonist of histamine and
platelet-activating factor receptors, on human cardiac Kv1.5 channels.Br J Pharmacol, 128(5), 1071-1081.
Castle NA (1990). Bupivacaine inhibits the transient outward
K+ current but not the inward rectifier in rat
ventricular myocytes. J Pharmacol Exp Ther, 255(3), 1038-1046.
Cheng A, & Merz KM (1996). Application of the Nosé-Hoover Chain
Algorithm to the Study of Protein Dynamics. J Phys Chem,100(1927–1937.
Choi KL, Mossman C, Aube J, & Yellen G (1993). The internal quaternary
ammonium receptor site of Shaker potassium channels.Neuron, 10(3), 533-541.
Clarkson CW, & Hondeghem LM (1985). Mechanism for bupivacaine
depression of cardiac conduction: fast block of sodium channels during
the action potential with slow recovery from block during diastole.Anesthesiology, 62(4), 396-405.
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA,
… Ahluwalia A (2018). Experimental design and analysis and their
reporting II: updated and simplified guidance for authors and peer
reviewers. Br J Pharmacol, 175(7), 987-993.
Decher N, Gonzalez T, Streit AK, Sachse FB, Renigunta V, Soom M, …
Sanguinetti MC (2008). Structural determinants of Kvbeta1.3-induced
channel inactivation: a hairpin modulated by PIP2.EMBO J, 27(23), 3164-3174.
Decher N, Kumar P, Gonzalez T, Pirard B, & Sanguinetti MC (2006).
Binding site of a novel Kv1.5 blocker: a ”foot in the door” against
atrial fibrillation. Mol Pharmacol, 70(4), 1204-1211.
Decher N, Kumar P, Gonzalez T, Renigunta V, & Sanguinetti MC (2005).
Structural basis for competition between drug binding and Kvbeta 1.3
accessory subunit-induced N-type inactivation of Kv1.5 channels.Mol Pharmacol, 68(4), 995-1005.
Decher N, Pirard B, Bundis F, Peukert S, Baringhaus KH, Busch AE, …
Sanguinetti MC (2004). Molecular basis for Kv1.5 channel block:
conservation of drug binding sites among voltage-gated
K+ channels. J Biol Chem, 279(1), 394-400.
Fedida D, Wible B, Wang Z, Fermini B, Faust F, Nattel S, & Brown AM
(1993). Identity of a novel delayed rectifier current from human heart
with a cloned K+ channel current. Circ Res,73(1), 210-216.
Franqueza L, Longobardo M, Vicente J, Delpon E, Tamkun MM, Tamargo J,
… Valenzuela C (1997). Molecular determinants of stereoselective
bupivacaine block of hKv1.5 channels. Circ Res, 81(6), 1053-1064.
Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA,
… Mainz DT (2006). Extra precision glide: docking and scoring
incorporating a model of hydrophobic enclosure for protein-ligand
complexes. J Med Chem, 49(21), 6177-6196.
Gonzalez T, Longobardo M, Caballero R, Delpon E, Tamargo J, &
Valenzuela C (2001). Effects of bupivacaine and a novel local
anesthetic, IQB-9302, on human cardiac K+ channels. J Pharmacol
Exp Ther, 296(2), 573-583.
Gonzalez T, Navarro-Polanco R, Arias C, Caballero R, Moreno I, Delpon E,
… Valenzuela C (2002). Assembly with the Kvbeta1.3 subunit modulates
drug block of hKv1.5 channels. Mol Pharmacol, 62(6), 1456-1463.
Hamill OP, Marty A, Neher E, Sakmann B, & Sigworth FJ (1981). Improved
patch-clamp techniques for high-resolution current recording from cells
and cell-free membrane patches. Pflugers Arch, 391(2), 85-100.
Hanner M, Green B, Gao YD, Schmalhofer WA, Matyskiela M, Durand DJ, …
Garcia ML (2001). Binding of correolide to the Kv1.3 potassium channel:
characterization of the binding domain by site-directed mutagenesis.Biochemistry, 40(39), 11687-11697.
Hockerman GH, Dilmac N, Scheuer T, & Catterall WA (2000). Molecular
determinants of diltiazem block in domains IIIS6 and IVS6 of L-type
Ca2+ channels. Mol Pharmacol, 58(6), 1264-1270.
Kaminski GA, Friesner RA, Tirado-Rives J, & Jorgensen WL (2001).
Evaluation and reparametrization of the OPLS-AA force field for proteins
via comparison with accurate quantum chemical calculations on peptides.J Phys Chem B, 105(6474–6487.
Kiper AK, Rinné S, Rolfes C, Ramirez D, Seebohm G, Netter MF, … Decher
N (2015). Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1
as a target against atrial fibrillation and obstructive sleep apnea?Pflugers Arch, 467(5), 1081-1090.
Kotelko DM, Shnider SM, Dailey PA, Brizgys RV, Levinson G, Shapiro WA,
… Rosen MA (1984). Bupivacaine-induced cardiac arrhythmias in sheep.Anesthesiology, 60(1), 10-18.
Lipka LJ, Jiang M, & Tseng GN (1998). Differential effects of
bupivacaine on cardiac K channels: role of channel inactivation and
subunit composition in drug-channel interaction. J Cardiovasc
Electrophysiol, 9(7), 727-742.
Long SB, Campbell EB, & Mackinnon R (2005). Crystal structure of a
mammalian voltage-dependent Shaker family K+channel. Science, 309(5736), 897-903.
Long SB, Tao X, Campbell EB, & MacKinnon R (2007). Atomic structure of
a voltage-dependent K+ channel in a lipid
membrane-like environment. Nature, 450(7168), 376-382.
Longobardo M, Delpon E, Caballero R, Tamargo J, & Valenzuela C (1998).
Structural determinants of potency and stereoselective block of hKv1.5
channels induced by local anesthetics. Mol Pharmacol, 54(1),
162-169.
Martyna GJ, Tobias DJ, & Klein ML (1994). Constant pressure molecular
dynamics algorithms. J Chem Phys, 101(4177–4189.
Marzian S, Stansfeld PJ, Rapedius M, Rinne S, Nematian-Ardestani E,
Abbruzzese JL, … Decher N (2013). Side pockets provide the basis for a
new mechanism of Kv channel-specific inhibition. Nat Chem Biol,9(8), 507-513.
Mitcheson JS, Chen J, Lin M, Culberson C, & Sanguinetti MC (2000). A
structural basis for drug-induced long QT syndrome. Proc Natl Acad
Sci U S A, 97(22), 12329-12333.
Moreno I, Caballero R, Gonzalez T, Arias C, Valenzuela C, Iriepa I, …
Delpon E (2003). Effects of irbesartan on cloned potassium channels
involved in human cardiac repolarization. J Pharmacol Exp Ther,304(2), 862-873.
Sali A, & Blundell TL (1993). Comparative protein modelling by
satisfaction of spatial restraints. J Mol Biol, 234(3), 779-815.
Sanchez-Chapula J (1988). Effects of bupivacaine on membrane currents of
guinea-pig ventricular myocytes. Eur J Pharmacol, 156(3),
303-308.
Scott DB, Lee A, Fagan D, Bowler GM, Bloomfield P, & Lundh R (1989).
Acute toxicity of ropivacaine compared with that of bupivacaine.Anesth Analg, 69(5), 563-569.
Shieh CC, & Kirsch GE (1994). Mutational analysis of ion conduction and
drug binding sites in the inner mouth of voltage-gated
K+ channels. Biophys J, 67(6), 2316-2325.
Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, & Sherman W (2010).
Prediction of Absolute Solvation Free Energies using Molecular Dynamics
Free Energy Perturbation and the OPLS Force Field. J Chem Theory
Comput, 6(5), 1509-1519.
Snyders DJ, Tamkun MM, & Bennett PB (1993). A rapidly activating and
slowly inactivating potassium channel cloned from human heart.
Functional analysis after stable mammalian cell culture expression.J Gen Physiol, 101(4), 513-543.
Streit AK, Netter MF, Kempf F, Walecki M, Rinné S, Bollepalli MK, …
Decher N (2011). A specific two-pore domain potassium channel blocker
defines the structure of the TASK-1 open pore. J Biol Chem,286(16), 13977-13984.
Strutz-Seebohm N, Gutcher I, Decher N, Steinmeyer K, Lang F, & Seebohm
G (2007). Comparison of potent Kv1.5 potassium channel inhibitors
reveals the molecular basis for blocking kinetics and binding mode.Cell Physiol Biochem, 20(6), 791-800.
Stühmer W (1992). Electrophysiological recording from Xenopus oocytes.Methods Enzymol, 207(319-339.
Tikhonov DB, & Zhorov BS (2014). Homology modeling of Kv1.5 channel
block by cationic and electroneutral ligands. Biochim Biophys
Acta, 1838(3), 978-987.
Valenzuela C, Delpon E, Franqueza L, Gay P, Snyders DJ, & Tamargo J
(1997). Effects of ropivacaine on a potassium channel (hKv1.5) cloned
from human ventricle. Anesthesiology, 86(3), 718-728.
Valenzuela C, Delpon E, Tamkun MM, Tamargo J, & Snyders DJ (1995).
Stereoselective block of a human cardiac potassium channel (Kv1.5) by
bupivacaine enantiomers. Biophys J, 69(2), 418-427.
Yellen G, Jurman ME, Abramson T, & MacKinnon R (1991). Mutations
affecting internal TEA blockade identify the probable pore-forming
region of a K+ channel. Science, 251(4996),
939-942.
Yeola SW, Rich TC, Uebele VN, Tamkun MM, & Snyders DJ (1996). Molecular
analysis of a binding site for quinidine in a human cardiac delayed
rectifier K+ channel. Role of S6 in antiarrhythmic
drug binding. Circ Res, 78(6), 1105-1114.